IDEXX Laboratories stock (US45168D1046): Q1 earnings beat with raised FY guidance

IDEXX Laboratories reported Q1 2026 EPS of $3.47, beating estimates by $0.06, with revenue up 14.3% to $1.14 billion. The company raised its full-year guidance on May 5.

IDEXX Laboratories released its Q1 2026 earnings on May 5, 2026, posting adjusted EPS of $3.47, surpassing the consensus estimate of $3.41 by $0.06. Revenue climbed 14.3% year-over-year to $1.14 billion, exceeding expectations of $1.12 billion, according to MarketBeat as of May 5, 2026. The company also updated its FY 2026 guidance, projecting EPS of $14.45-$14.90 versus consensus of $14.52, and revenue of $4.7-$4.8 billion.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories
• Sector/industry: Healthcare / Veterinary diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Companion animal diagnostics, livestock tests
• Home exchange/listing venue: Nasdaq (IDXX)
• Trading currency: USD

IDEXX Laboratories: core business model

IDEXX Laboratories develops and manufactures diagnostic products and services for companion animal and livestock markets. The company offers point-of-care diagnostics, instruments, and reference lab services primarily to veterinarians worldwide. Its portfolio includes tests for diseases, wellness monitoring, and practice management software, generating the bulk of revenue from the U.S. companion animal segment.

Listed on Nasdaq under ticker IDXX, IDEXX Laboratories holds a leading position in veterinary diagnostics, benefiting from rising pet ownership trends in the U.S. and Europe. The stock traded at $560.11 on May 11, 2026, according to MarketBeat as of May 11, 2026.

Main revenue and product drivers for IDEXX Laboratories

Companion Animal Group (CAG) drives over 75% of revenue, fueled by IDEXX's Catalyst and ProCyte analyzers for in-clinic testing. Reference laboratories contribute through outsourced diagnostics, with Q1 2026 revenue growth reflecting strong U.S. demand published May 5, 2026. Livestock, Poultry and Dairy (LPD) adds diversification via water testing and poultry diagnostics.

Key products like SNAP tests for rapid heartworm and allergy detection support recurring consumables revenue. The Water segment serves municipal and industrial clients, providing steady growth amid U.S. infrastructure focus.

Industry trends and competitive position

The veterinary diagnostics market expands with pet humanization and preventive care trends in the U.S., where IDEXX commands significant share against peers like Zoetis. Its integrated ecosystem of hardware, software, and services creates high switching costs for vet practices.

Why IDEXX Laboratories matters for US investors

As a Nasdaq-listed leader in animal health, IDEXX Laboratories offers U.S. investors exposure to resilient healthcare spending on pets, mirroring human diagnostics growth. With substantial North American revenue, it ties directly to U.S. consumer trends and veterinary clinic expansion.

Conclusion

IDEXX Laboratories delivered a strong Q1 2026 earnings beat with revenue and EPS above expectations, alongside raised full-year guidance signaling confidence. The company's dominant position in veterinary diagnostics positions it well amid U.S. pet care demand. Investors track upcoming quarters for sustained growth momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.